Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: A systematic review with meta-analysis

European Journal of Cancer

Volumn 45, Issue 4, 2009, Pages 601-607

  Lima, João Paulo da Silveira Nogueira ^a   Santos, Lucas Vieira dos ^a   Sasse, Emma Chen ^b   Sasse, Andre Deeke ^a,c  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Dendrix Arquitetura da Informação Científica   (Brazil)

^c Radium Instituto de Oncologia   (Brazil)

Author keywords

Antineoplastic agents; Drug therapy; Lung neoplasms; Meta analysis; Non small cell lung carcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; LOMUSTINE; METHOTREXATE; MITOMYCIN; NAVELBINE; PACLITAXEL; VINBLASTINE;

ARTICLE; ASTHENIA; CANCER GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEVER; FLU LIKE SYNDROME; HUMAN; HYPOTENSION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; TREATMENT DURATION; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; HEMATOLOGIC DISEASES; HUMANS; LUNG NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 60149111149     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.11.006     Document Type: Article

References (27)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Chen F., Cole P., and Bina W.F. Time trend and geographic patterns of lung adenocarcinoma in the United States, 1973-2002. Cancer Epidemiol Biomarkers Prev 16 (2007) 2724-2729
3. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
4. SEER cancer statistics review, 1975-2005. National Cancer Institute; 2008. [accessed 2008].
5. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
6. Baggstrom M.Q., Stinchcombe T.E., Fried D.B., Poole C., Hensing T.A., and Socinski M.A. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol 2 (2007) 845-853
7. Bonfill X., Serra C., Sacristan M., Nogue M., Losa F., and Montesinos J. Second-line chemotherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2 (2002) CD002804
8. Noble J., Ellis P.M., Mackay J.A., and Evans W.K. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 1 (2006) 1042-1058
9. Shepherd F.A., Dancey J., Ramlau R., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 (2000) 2095-2103
10. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. New Engl J Med 353 (2005) 123-132
11. Belani C.P., Barstis J., Perry M.C., et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 21 (2003) 2933-2939
12. Buccheri G.F., Ferrigno D., Curcio A., Vola F., and Rosso A. Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study. Cancer 63 (1989) 428-432
13. Westeel V., Quoix E., Moro-Sibilot D., et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst 97 (2005) 499-506
14. Weynants P., Humblet Y., Jamarl J., et al. Additional treatment does not improve the survival of locally advanced or metastatic NSCLC patients who responded after two courses of cisplatin (C), vindesin (V), mitomycin (M) chemotherapy. Lung Cancer 18 (1997) 48
15. Johnson K.R., Ringland C., Stokes B.J., et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol 7 (2006) 741-746
16. Parmar M.K., Torri V., and Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17 (1998) 2815-2834
17. Tierney J.F., Stewart L.A., Ghersi D., Burdett S., and Sydes M.R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8 (2007) 16
18. Deeks J.J., Altman D.G., and Bradburn M.J. Systematic reviews in health care: Metaanalisys in context. 2nd ed. (2001), BMJ Publication Group, London
19. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
20. Higgins J.P., Thompson S.G., Deeks J.J., and Altman D.G. Measuring inconsistency in meta-analyses. BMJ 327 (2003) 557-560
21. Smith I.E., O'Brien M.E., Talbot D.C., et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 19 (2001) 1336-1343
22. Socinski M.A., Schell M.J., Peterman A., et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20 (2002) 1335-1343
23. Brodowicz T., Krzakowski M., Zwitter M., et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 52 (2006) 155-163
24. von Plessen C., Bergman B., Andresen O., et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Brit J Cancer 95 (2006) 966-973
25. Park J.O., Kim S.W., Ahn J.S., et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol 25 (2007) 5233-5239
26. Michiels S., Piedbois P., Burdett S., Syz N., Stewart L., and Pignon J.P. Meta-analysis when only the median survival times are known: a comparison with individual patient data results. Int J Technol Assess Health Care 21 (2005) 119-125
27. Ciuleanu T.E., Brodowicz C., Belani C.P., et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study. J Clin Oncol 26s (2008) abstr 8011